ANTIMICROBIAL SUSCEPTIBLE PERCENTAGE OF CLINICAL ISOLATED GRAM NEGATIVE BACTERIA (JAN-DEC 2018)

DIVISION OF MICROBIOLOGY LABORATORY MAHARAJ NAKORN CHIANG MAI HOSPITAL

| | ORGANISM | NUMBER OF ISOLATED | Amikacin | Beta-lactam | | | | | | | | | Fluoroquinolone | | Trimethoprim/Sulfamethoxazole |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | Ampicillin | Amoxicillin/Clavulanic acid | Piperacillin/Tazobactam | Cefotaxime | Ceftazidime | Imipenem | Meropenem | Doripenem | Ertapenem | Ciprofloxacin | Levofloxacin | |
| Enterobacteriaceae | *Citrobacter freundii* | 83 | 98 | R | R | 83 | 73 | 72 | 93 | 93 | | 92 | 77 | 81 | 81 |
| | *Citrobacter koseri* | 78 | 100 | R | 33 | 100 | 92 | 92 | 100 | 100 | | 100 | 96 | 97 | 92 |
| | *Enterobacter aerogenes* | 186 | 98 | R | R | 87 | 75 | 75 | 98 | 99 | | 96 | 91 | 94 | 86 |
| | *Enterobacter cloacae* | 462 | 93 | R | R | 85 | 64 | 65 | 94 | 94 | | 90 | 80 | 87 | 73 |
| | *Enterobacter* spp. | 153 | 89 | R | R | 80 | 54 | 55 | 90 | 87 | | 84 | 70 | 77 | 59 |
| | *Escherichia coli* | 3030 | 99 | | 83 | 96 | 65 | 74 | 98 | 98 | | 98 | 49 | 49 | 45 |
| | *Klebsiella oxytoca* | 88 | 100 | R | 97 | 100 | 95 | 97 | 100 | 100 | | 100 | 95 | 95 | 95 |
| | *Klebsiella pneumoniae* | 1631 | 94 | R | 73 | 88 | 67 | 68 | 93 | 92 | | 92 | 71 | 79 | 64 |
| | *Morganella morganii* | 168 | 99 | R | R | 98 | 85 | 88 | 62 | 98 | | 98 | 77 | 86 | 70 |
| | *Proteus mirabilis* | 394 | 100 | | 91 | 99 | 80 | 95 | 99 | 100 | | 100 | 71 | 73 | 52 |
| | *Proteus vulgaris* | 89 | 100 | R | 92 | 100 | 94 | 98 | 98 | 100 | | 100 | 91 | 91 | 76 |
| | *Providencia rettgeri* | 45 | 100 | R | R | 98 | 89 | 89 | 89 | 98 | | 98 | 87 | 89 | 84 |
| | *Providencia stuartii* | 38 | 100 | R | R | 97 | 95 | 95 | 87 | 100 | | 100 | 89 | 89 | 87 |
| | *Salmonella enterica* | 202 | | 48 | | | | | | | | | 87 | | 83 |
| | *Serratia marcescens* | 161 | 99 | R | R | 98 | 96 | 98 | 99 | 99 | | 99 | 97 | 98 | 94 |
| | *Aeromonas* spp. | 93 | 99 | | 6 | 84 | 86 | 88 | 91 | 95 | | 81 | 94 | 97 | 89 |
| Non-fermentative bacilli | *Acinetobacter baumannii* | 886 | 55 | R | R | 35 | | 38 | 34 | 33 | | R | 36 | | |
| | *Acinetobacter* spp. | 78 | 86 | | | 83 | | 73 | 83 | 76 | | | 83 | | |
| | *Burkholderia cepacia* complex | 199 | | R | R | | | 95 | | 95 | | | | | 95 |
| | *Pseudomonas aeruginosa* | 1364 | 95 | R | R | 91 | R | 89 | 80 | 86 | 87 | R | 89 | 88 | R |
| | *Stenotrophomonas maltophilia* | 446 | R | R | R | R | R | | R | R | R | R | | 93 | 95 |
| | *Haemophilus influenzae* | 210 | | 71 | 99 | | 100 | | | | | | 99 | | 50 |

R (Intrinsic resistance) <50% 50-69% 70-89% 90-100%

ANTIMICROBIAL SUSCEPTIBLE PERCENTAGE OF CLINICAL ISOLATED GRAM POSITIVE BACTERIA (JAN-DEC 2018)

DIVISION OF MICROBIOLOGY LABORATORY MAHARAJ NAKORN CHIANG MAI HOSPITAL

| ORGANISM | NUMBER OF ISOLATES | Ampicillin | Penicillin | Oxacillin | Cefotaxime | Erythromycin | Clindamycin | Levofloxacin | Trimethoprim/Sulfamethoxazole | Vancomycin | Gentamicin (high level)* |
|---|---|---|---|---|---|---|---|---|---|---|---|
| *Staphylococcus aureus* | 1184 | | | 91 | | 87 | 88 | | 99 | | |
| Coagulase-negative staphylococci (CoNS) | 355 | | | 44 | | 32 | 47 | | 66 | | |
| *Enterococcus faecalis* | 929 | 99 | 83 | | R | | R | | R | 100 | 52 |
| *Enterococcus faecium* | 611 | 4 | 4 | | R | | R | | R | 78 | 74 |
| *Enterococcus* spp. | 86 | 73 | 70 | | R | | R | | R | 99 | 92 |
| *Streptococcus pyogenes* (Group A) | 99 | | 100 | | | 90 | 94 | 100 | | | |
| *Streptococcus agalactiae* (Group B) | 200 | | 100 | | | 76 | 73 | 98 | | | |
| *Streptococcus pneumoniae* | 120 | | 95 | | | 57 | 69 | 97 | 48 | | |
| Viridans Streptococci | 248 | | | | 100 | 66 | 78 | 90 | | 100 | |
| *Streptococcus gallolyticus* | 75 | | | | 100 | 34 | 47 | 95 | | 100 | |

* High level gentamicin susceptible refers to synergy effect with beta-lactam or vancomycin

R (Intrinsic resistance) <50% 50-69% 70-89% 90-100%